


# Stock Selection Guide ®

The most widely used aid to good investment judgment

Company STRYKER CORE	)		Da	te <u>01/</u>	05/06
Prepared by jah	Г	Oata tal	ken from	NAI	C Data
Where traded NYSE	Major pro	oduct/s	ervice [	Health	Care
CAPITALIZATION Outstanding	g Amounts	Ref	erence -		
Preferred(\$M)	0.0	% Ir	nsiders	% Inst	itution
Common(M Shares)	403.9		0.0	0	.0
Debt(\$M) 9.0	% to Tot.Cap.	0.3	% Poten	tial Dil.	None



	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	LAST 5 YEAR AVG.	TREND	
	1993	1990	1331	1336	1333	2000	2001	2002	2003	2004		UP	DOWN
A % Pre-tax Profit on Sales (Net Before Taxes ÷ Sales)	16.9	18.6	19.8	17.5	11.7	14.6	15.6	17.4	18.2	19.7	17.1	UP	
B % Earned on Equity (E/S ÷ Book Value)	19.2	19.7	20.1	18.5	23.5	25.2	25.0	23.1	20.9	20.9	23.0		DOWN

56 320

44 850 HIGHTHIC VEAD

## PRICE-EARNINGS HISTORY as an indicator of the future

This shows how stock prices have fluctuated with earnings and dividends. It is a building block for translating earnings into future stock prices.

		PRESE	NT PRICE	44.830	H	IGH THIS YEAR		LOW IH	IS YEAR	39.740
Year		A PRICE B		C Earnings Per		D E Price Earnings Ratio D		F Dividend	G % Payout	H % High Yield
		HIGH	LOW	Share		HIGH A ÷ C	LOW B ÷ C	Per Share	F ÷ C X 100	F ÷ B X 100
1	2000	28.9	12.2	0.55	_	52.5	22.2	0.040	7.3	0.3
2	2001	31.6	21.7	0.67		47.2	32.4	0.050	7.5	0.2
3	2002	33.7	21.9	0.88		38.5	25.0	0.060	6.9	0.3
4	2003	42.7	29.8	1.13		38.0	26.5	0.070	6.2	0.2
5	2004	57.7	40.3	1.43		40.3	28.2	0.090	6.3	0.2
6	TOTAL		125.9			116.8	79.7		34.2	
7	AVERAGE		25.2			38.9	26.6		6.8	
8	AVERAGE PR	ICE EARNINGS RAT	10 32	.8	9	CURRENT PRICE	CE EARNINGS RA	TIO	26.9	

### Proj. P/E [23.35] Based on Next 4 qtr. EPS [1.92] **EVALUATING RISK and REWARD over the next 5 years**

Current P/E Based on Last 4 qtr. EPS [1.67] PEG=179

01/05/06

39 740

Assuming one recession and one business boom every 5 years, calculations are made of how high and how low the stock might sell. The upside-downside ratio is the key to evaluating risk and reward. A HIGH PRICE -- NEXT 5 YEARS 38.9 30.0 3.36 100.8 Avg. High P/E \_\_\_ X Estimate High Earnings/Share = Forecast High Price \$ (3D7 as adi.) (4A1) **B LOW PRICE -- NEXT 5 YEARS** 26.6 19.1 X Estimated Low Earnings/Share 1.43 **1.67** = \$ 31.9 (a) Avg. Low P/E 25.2 (b) Avg. Low Price of Last 5 Years = (3B7) (c) Recent Severe Market Low Price = 0.090 27.5 (d) Price Dividend Will Support Present Divd. 0.003 High Yield 31.9 Selected Estimate Low Price C ZONING 100.8 31.9 68.9 17.2 Low Forecast Price Equals High Forecast Price Minus Range. 1/3 of Range = (4A1) (4C2) Lower 1/3 = 31.9 49.1 (Buy) Note: Ranges changed to 25%/50%/25% (4C3) Middle 1/3 = 49.1 83.6 (Mavbe) (4C4) Upper 1/3 = 83.6 100.8 (4A1) (Sell) 44.850 Buy Present Market Price of D UP-SIDE DOWN-SIDE RATIO (Potential Gain vs. Risk of Loss) High Price (4A1) 100.8 Minus Present Price 44.850 31.9 44.850 Minus Low Price (4B1) (4D) E PRICE TARGET (Note: This shows the potential market price appreciation over the next five years in simple interest terms.) 100.8 High Price (4A1) 124.7 2.247 224.7 ) X 100 = ( ) - 100 =

## 44.850

Relative Value: 82.0% Proj. Relative Value: 71.2%


**5-YEAR POTENTIAL** This combines price appreciation with dividend yield to get an estimate of total return. It provides a standard for comparing income and growth stocks. Note: Results are expressed as a simple rate; use the table below to convert to a compound rate. 0.090 A Present Full Year's Dividend \$

X 100 = Present Yield or % Returned on Purchase Price Present Price of Stock 44.850 \$ **B AVERAGE YIELD OVER NEXT 5 YEARS** 

## Avg. Earnings Per Share Next 5 Years

2.54 X Avg. % Payout (3G7) 17.3 44.850 Present Price \$

C ESTIMATED AVERAGE ANNUAL RETURN OVER NE 5 Year Appreciation Potential (4E) 124.7	XT FIVE YEAR	RS			P.A.R.	Tot. Ret.
5 real Appreciation Fotential		24.9	0/	Average Yield	0.3%	0.2%
Average Yield (5B)			— <sup>70</sup>	Annual Appreciation	13.0%	17.6%
Average Total Annual Return Over the Next 5 Years	(5C)	25.3	_ %	% Compd Ann Rate of Ret	13.2%	17.8%
		23.3	%			



other products (5.8%). Orthopaedic products include hip, knee, shoulder, and spinal implants. MedSurg includes powered instruments, endoscopic systems, other operating room devices, specialty stretchers, and maternity beds. Other includes Physical

15,890 employees, 3,785 stockholders. Off. and dir. (incl. Stryker family trust) own 27.7% of stock (3/05 proxy). Pres. & CEO: Stephen MacMillan. Inc.: Ml. Address: P.O.Box 4085, Kalamazoo, MI 49003. Tel.: 616-385-2600. Web site: www.strykercorp.com

ANNUAL RATES Est'd '02-'04 Past Past 5 Yrs. 20.5% 27.0% 25.5% of change (per sh) 10 Yrs. to '08-'10 20.0% 24.0% 22.0% Sales "Cash Flow" 18.0% 20.5% Earnings Dividends Book Value 15.0% 26.0% QUARTERLY SALES (\$ mill.)

1397.6

137.8

705.4

850.5

**Current Assets** 

Accts Payable Debt Due

Current Liab.

489.6

2365.2

171.4

856.

1035.6

8 1

2142.6

214.5 9.3

889.7

1113.5

endar		Jun.30			Year
2002	702.9	733.9	745.6	829.2	3011.6
2003	846.9	891.7	885.4	1001	3625.3
2004	1035	1043	1029	1155	4262.3
	1202	1219	1172	1297	4890
2006	1340	1360	1340	1475	5515
Cal-	E/	RNINGS F	PER SHAR	ΕA	Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2002	.20	.21	.21	.26	.88
2003	.26	.27	.26	.33	1.12
2004	.33	.37	.33	.40	1.43
2005	.42	.45	.40	.48	1.75
2006	.50	.53	.49	.58	2.10
Cal-	AN	NUAL DIV	IDEND PA	IDв	Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2001	.04				.04
2002	.05				.05
2003	.06				.06
2004	.07				.07
2005	09				l

Anxiety over Stryker's capacity to maintain a 20%-plus bottom-line track is pressuring the company's stock. Although SYK shares have recovered a few points in recent weeks, they are down 15% since our September report. Most of the damage followed the release of third-quarter results, which revealed sales and earnings that were a tad shy of expectations. The causes of the shortfall were disconcerting as, too, were management comments regarding the pricing environment. The company still expects a 20% share-net advance in 2006, but, clearly, Wall Street isn't as sanguine. For three decades, Stryker has consistently scored annual gains of at least 20%, so investors are hypersensitive to any whiff that this extraordinary record is in jeopardy; the one exception is 1989, when a huge purchase hurt profits. There are multiple reasons for con-

cern. Revenue growth slowed to 13.9% in the September quarter from the 16.5% achieved in the year's first half. Significantly, too, much of the gains came from persistent strength (up 20.5%) in the low-margined MedSurg business. The far more important Orthopaedic Implant seg-

ment expanded a relatively modest 10.6% (to \$678 million), down from 13.9% in the preceding six months. Stryker's hips and knees units are ostensibly being squeezed by both market-share losses and pricing pressures. Domestic sales of hips fell 2% (to \$206 million), marking the first quarterly decline in years. Looking forward, the company may have to contend with flat pricing in the reconstruction market, while working to boost unit volume. Moreover, prevailing inflationary and interest-rate trends suggest that foreign currency dynamics could reverse course and become a headwind in 2006.


We continue to like these good-quality shares. Earnings momentum remains positive, as do worldwide demographic trends. Stryker's R&D program has several decent prospects, and its financial strength affords a well-regarded management team the flexibility to enhance share net through both acquisitions and stock repurchases. Last, valuations are at multiyear lows, allowing for superior 3- to 5-year returns, even if earnings growth were to fall below the "magical" 20% threshold George Rho December 2, 2005

(A) Based on average shares through '96; \$0.01; '02, \$0.03; '04, \$0.29; '05, \$0.08. Next diluted thereafter. Excludes extraordinary gains of \$0.06 in 1990; \$0.03 in 1996. Excludes non-ically paid at the end of January. (C) Includes recurring losses: '98, \$0.57; '99, \$0.71; '01,

intangibles. In 2004: \$963.2 million,

Company's Financial Strength Stock's Price Stability 85 Price Growth Persistence 100 **Earnings Predictability** 100

© 2005, Value Line Publishing, Inc. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product



 $2nd\ 3rd\ 4th\ 1st\ 2nd\ 3rd\ 4th\ 2nd\ 3rd\ 4th\$